Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 444 participants.
Also called NCT05391893
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 444 participants
- Sponsor
- Corewell Health South
- Registry
-
NCT05391893
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05391893. Non-randomized; no masking; primary purpose treatment. Start 2020-06-19 (actual); primary completion 2023-04-01 (actual). Results posted on 2024-12-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Condition
- Atrial Flutter
- Intervention (Drug)
- Oral
- Intervention (Drug)
- Intravenous drug
- Lead sponsor
- Corewell Health South
Record details
- Record id
cardio:ct-nct05391893- Content hash
71fa76a41b92f91e95c3e30ce4c86a313bb24141ee61b29fd5d921e60a15172a